Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer in Germany: population-based data with multicenter validation from 2016 to 2020doi:10.1055/s-0043-1766222Flegar, L.Thoduka, S.Librizzi, D.Luster, M.Zacharis, A....
Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricaciesTheranostic principles utilize a molecular biomarker specific for a tumor target, initially for imaging to assess target expression and, if deemed suitable, for targeted therapy. This presents an exciting ...
(177)Lu-PSMA demonstrated high absorbed tumor doses (median, 3.3 mGy/MBq) as compared to normal organs. Parotid glands received higher doses (1.3 mGy/MBq) than kidneys (0.8 mGy/MBq). All patients tolerated the therapy without any acute adverse effects. Except mild reversible xerostomia in ...
Besides Lutetium-177 PSMA Therapy for prostate care, Farrer Park Hospital also offers Focal Therapy, anon-invasive procedure that treats early-stage prostate cancer using high intensity focused ultrasound. For non-cancerous enlargement of the prostate, the Prolieve® Therm...
Shared insight from Rana McKay, MD, and the Oncology Brothers on updated data from PSMAfore and the use of Lutetium-177–PSMA-617 in patients with metastatic castration-resistant prostate cancer.
药物别名 177Lu-PSMA-617 药效学 Lutetium Lu 177 vipivotide tetraxetan is a radioligand that exerts cytotoxic effects on cancer cells. Tumor uptake value is 11.2%ID/g. In clinical trials of patients with metastatic castration-resistant prostate cancer, treatment with lutetium Lu 177 vipivotide te...
FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Targeted Radioligand Therapy for Treatment of Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer FDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 f...
It's not chemotherapy. It's the FIRST and ONLY PSMA+ targeted radioligand therapy. Find out if PLUVICTO could be the next step for you or a loved one. Follow these links to explore why: If you or a loved one has started on PLUVICTO, here's what you need to know: ...
suspected metastasis who are candidates for initial definitive therapy; with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level; and for selection of patients with metastatic prostate cancer, for whom lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated...
177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging 2017; 44: 81–91. Article CAS PubMed Google Scholar Kirby M, Hirst C, Crawford ED . Characterising the castration-resistant prostate ...